Ironwood Pharma (IRWD) Misses Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Ironwood Pharma (IRWD) Misses Q1 EPS by 4c

Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

May 5, 2022 7:00 AM EDT

LINZESS® (Iinaclotide) prescription demand growth increased 11% year-over-year; LINZESS U.S. net sales of $232 million, an increase of 8% year-over-year

Total revenue of $98 million; U.S. LINZESS collaboration revenue of $94 million

GAAP net income of $39 million and adjusted EBITDA of $58 million; ended Q1 2022 with $593 million in cash and cash equivalents

BOSTON--(BUSINESS... More